-

Sensorion Will Take Part in a Press Conference Launching the Annual UNESCO Week of Sound

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation of its management team in a virtual press conference launching the annual UNESCO Week of Sound, an event sponsored by Sensorion, on January 10, 2023.

Géraldine Honnet, Sensorion’s Chief Medical Officer, will take part in a virtual press conference launching the annual UNESCO Week of Sound (La Semaine du Son de l’UNESCO), an event sponsored by Sensorion, on January 10, 2023. The press conference will address the “Hearing health: scientific breakthroughs and new hopes for tomorrow.”

Access the replay of the press conference on the UNESCO Week of Sound website on January 10, 2023, at 11 am CET, by clicking on this link.

Press conference: “Hearing health: scientific breakthroughs and new hopes for tomorrow”
Date: Tuesday, January, 10, 2023
Speaker: Géraldine Honnet, Chief Medical Officer
Event: UNESCO Week of Sound

About Sensorion

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need.

Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. Its portfolio combines both small molecule and inner ear gene therapies programs.

Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 Proof of Concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, in a study of SENS-401 in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022.

Sensorion pursues its broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including OTOF-GT, targeting deafness caused by a mutation of the gene encoding for otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children (GJB2-GT). The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.

www.sensorion.com

Label: SENSORION
ISIN: FR0012596468
Mnemonic: ALSEN

Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2021 full year financial report published on April 28, 2022, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.

Contacts

Investor Relations
Noemie Djokovic
Investor Relations and Communications
+33 6 76 67 98 31
ir.contact@sensorion-pharma.com

International Media Relations
Consilium Strategic Communications
Matthew Cole/Jessica Hodgson
+44 7593 572720
+44 7561 424788
Sensorion@consilium-comms.com

Sensorion

BOURSE:ALSEN

Release Summary
Sensorion will take part in a press conference launching the annual UNESCO Week of Sound
Release Versions

Contacts

Investor Relations
Noemie Djokovic
Investor Relations and Communications
+33 6 76 67 98 31
ir.contact@sensorion-pharma.com

International Media Relations
Consilium Strategic Communications
Matthew Cole/Jessica Hodgson
+44 7593 572720
+44 7561 424788
Sensorion@consilium-comms.com

More News From Sensorion

Sensorion Announces its Participation in the European Society of Gene & Cell Therapy (ESGCT) Annual Congress

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) (“the Company”), a pioneering clinical-stage biotechnology company that develops novel therapies to restore hearing and to treat and prevent hearing loss disorders, today announced its participation in the 33rd European Society of Gene & Cell Therapy (ESGCT) Annual Congress, taking place on October 27-30, 2026, at the Congress Center Hamburg (CCH), in Hamburg, Germany. Lise Barrot, Pre...

Sensorion Announces the Appointment of Peter Weber, MD, MBA, as Chief Medical Officer

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) (“the Company”), a pioneering clinical-stage biotechnology company that develops novel therapies to restore hearing and to treat and prevent hearing loss disorders, today announced the appointment of Peter Weber, MD, MBA, as Chief Medical Officer, effective November 2, 2026. Dr. Weber is an otologist and neurotologist with more than two decades of clinical and industry leadership in hearin...

Sensorion Announces the Appointment of Louis J. Arcudi III as Chief Financial Officer

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) (“the Company”) a pioneering clinical-stage biotechnology company focused on developing novel therapies to restore hearing and treat and prevent hearing loss disorders, today announced the appointment of Louis “Lou” J. Arcudi III as Chief Financial Officer, effective October 7, 2026. Lou Arcudi will be based in the Boston area and will report to Fred Chereau, Chief Executive Officer. He su...
Back to Newsroom